妊娠期高血压疾病患者产后医疗资源利用与不同降压药血压控制情况
本回顾性队列研究纳入2019年4月至2023年6月单中心分娩并纳入远程血压监测项目的1507例妊娠期高血压疾病患者,比较出院时单用拉贝洛尔(488例)与硝苯地平(1019例)的产后结局。拉贝洛尔组产后8周内再入院率高于硝苯地平组(9.2% vs 3.9%,P<.001),校正后aOR 2.70(95%CI 1.57-4.65),急诊就诊无显著差异。
要点
- 出院时单用拉贝洛尔者产后再入院率9.2%,高于硝苯地平者3.9%(P<.001)。
- 校正后拉贝洛尔再入院aOR 2.70(95%CI 1.57-4.65),急诊就诊aOR 1.01(95%CI 0.67-1.52)。
- 产后前10天拉贝洛尔组家庭血压处于严重范围的比例高于硝苯地平组。
核心结论
- 与出院时用硝苯地平相比,妊娠期高血压疾病患者出院时用拉贝洛尔与产后再入院 odds 增加相关。
- 作者认为这一现象可能由产后前10天家庭监测中更严重的血压升高所驱动。
研究设计与样本
- 回顾性队列研究,评估2019年4月至2023年6月单中心分娩的产后个体出院时降压药类型与结局的关系。
- 共纳入1507例妊娠期高血压疾病并纳入本机构远程血压管理项目的患者,排除产前已用降压药者。
- 暴露为出院时单用拉贝洛尔(488例,32.4%) vs 硝苯地平(1019例,67.6%)。
- 本机构远程项目监测血压至产后6个月。
- 主要结局为分娩后8周内产后再入院和急诊就诊。
主要发现
- 拉贝洛尔组BMI更高、孕前高血压比例更高。
- 硝苯地平组产后再入院率低于拉贝洛尔组(3.9% vs 9.2%,P<.001)。
- 多因素logistic回归校正HDP严重程度、TIS、种族和BMI后,拉贝洛尔再入院aOR 2.70(95%CI 1.57-4.65),急诊就诊aOR 1.01(95%CI 0.67-1.52)。
- 按孕前高血压分层后结果相似。
- 产后前10天,拉贝洛尔组每日家庭血压处于严重范围的比例高于硝苯地平组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertensive disorders of pregnancy are a significant contributor to maternal morbidity and mortality in the postpartum period and are the leading cause of postpartum readmission following delivery hospitalization. At present, there remains uncertainty regarding differences in postpartum health care utilization for individuals discharged on specific antihypertensive agents while enrolled in an institutional remote blood pressure (BP) monitoring program. OBJECTIVE: To evaluate rates of postpartum hospital readmission and emergency room (ER) utilization for individuals with a hypertensive disorder of pregnancy (HDP) enrolled in remote BP monitoring after discharge on labetalol vs nifedipine. STUDY DESIGN: We performed a retrospective cohort study to evaluate outcomes associated with the type of antihypertensive medication at discharge in postpartum individuals delivering between April 2019 and June 2023 at a single institution. The exposure of interest was discharge on single-agent labetalol vs nifedipine. Individuals were included who were diagnosed with hypertension (HTN) in pregnancy (including pre-pregnancy HTN) and were enrolled in our institution's remote BP management program. Our institution's remote program monitors BP up to 6 months postpartum. Individuals were excluded if they were prescribed antihypertensives antenatally. We compared demographics, clinical outcomes, and home BP measures between groups. The primary outcome was postpartum hospital readmission and ER visits within 8 weeks of delivery. Multivariate logistic regression models adjusted for severity of HDP, TIS, race, and BMI. RESULTS: 1507 individuals were included; 488 (32.4%) were discharged on labetalol and 1019 (67.6%) on nifedipine. Those discharged on labetalol had higher BMIs and higher rates of pre-pregnancy HTN. Compared to individuals discharged on labetalol, those discharged on nifedipine were less likely to have a postpartum hospital readmission (9.2% vs 3.9%, P<.001). In multivariate logistic regression models, discharge on labetalol was associated with a significant increased odds of postpartum hospital readmission [aOR 2.70 (95% CI 1.57-4.65)] but not ED visits [aOR 1.01 (95% CI 0.67-1.52)] compared with discharge on nifedipine. These findings were similar with stratification by pre-pregnancy HTN. Upon analysis of home postpartum BP data, we found that the proportion of blood pressures in the severe range by each postpartum day was higher in the first ten days postpartum for those discharged on labetalol as compared to nifedipine. CONCLUSION: Discharge on labetalol was associated with an increased odds of postpartum hospital readmission following a HDP compared with discharge on nifedipine. Our findings suggest this may be driven by more severe hypertension on home monitoring by each day postpartum in the first ten days postpartum.
引用
- Bennett C, Lemon L, Venkatakrishnan K, et al. Postpartum health-care utilization and blood pressure control by antihypertensive agent in hypertensive disorders of pregnancy. Am J Obstet Gynecol MFM. 2025. PMID: 41207561. doi:10.1016/j.ajogmf.2025.101836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。